Videos

Tanya Dorff, M.D., breaks down early ABBV-969 data showing strong responses in heavily pretreated mCRPC at ASCO 2026.

A study participant in teh trial of daraxonrasib felt like he was part of something special, says UT MD Anderson's Subam Pant, "and he is."

In the final episode, ‘The Future Landscape: Topical vs. Systemic JAK Inhibitors in Vitiligo ,’ the panelists explored the following critical questions:

The second-line drug for metastatic pancreatic cancer is pan-RAS inhibitor that recruits cyclophilin A to stick to RAS proteins, explains Subham Pant, M.D., M.B.B.S., of The University of Texas MD Anderson Cancer Center.

In an interview before the annual ASCO meeting, Eduardo Vilar-Sanchez, M.D., Ph.D., of the University of Texas MD Anderson Cancer Center, talks about NOUS-209, an immunotherapy being studied to prevent cancer in those with Lynch syndrome mutations.

Eduardo Vilar-Sanchez, M.D., Ph.D., of the University of Texas MD Anderson Cancer Center, was awarded for his work in cancer immunoprevention and his efforts to develop a cancer vaccine for those who are carriers of Lynch mutations.

Treatment after treatment for second-line treatment for pancreatic cancer has failed in clinical trials. Daraxonrasib seems to have broken the losing streak, says MD Anderson's Shubman Pant, M.D., M.B.B.S.

Lead ARACOG trial investigator Alicia Morgans, M.D., discusses the importance of including cognitive effects in the conversation around prostate cancer treatment.

A new investigational combination therapy for advanced KRAS G12C-mutant non-small cell lung cancer showed "highly promising" results with “manageable” side effects, according to the study’s lead author.

Ferdinandos Skoulidis, M.D., Ph.D., explains what’s next for this treatment for patients with previously untreated advanced or metastatic KRAS G12C-mutated non-small cell lung cancer.

Divarasib plus pembrolizumab shows strong responses in patients with advanced KRAS G12C+ non-small cell lung cancer, according to the results of the Krascendo 170 study, presented today at ASCO 2026.

Dana-Farber’s Katherine Janeway, M.D., discusses how reimbursement policies for molecular diagnostics have failed to keep pace with scientific evidence, leaving gaps in the care for pediatric bone cancer patients.

Dana-Farber’s Katherine Janeway, M.D., discusses how molecular biomarkers inform treatment decisions in children and adolescents with the bone cancers Ewing sarcoma and osteosarcoma.

Bispecific antibodies are a major advance in multiple myeloma treatment with outstanding efficacy, with many clinical trials underway that are providing the evidence for using them in earlier lines of treatments.

Health systems and clinics need to work together to manage care of the potentially dangerous side effects of bispecific antibodies during the early, step-up phase of treatment, Adams said. Those side effects include cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.

In ‘A Milestone in Vitiligo: Clinical Efficacy and Long-Term Repigmentation Trends,’ the expert dermatologist examined the following critical questions:

Adams said she has seen firsthand the difference that bispecific antibodies have made. “Patients that would have never gotten into remission are getting into remission. Patients that would have never seen the birth of their grandchild are now seeing the birth of their grandchild,” Adams said. Some real-world data are showing slightly reduced efficacy that was seen in clinical trials, Adams said. There is a need for research that would develop comparator data to other therapies, she noted.

LINKER-MM4 is an open-label study of linvoseltamab as monotherapy in patients who have been newly diagnosed with multiple myeloma. Adams said the results are showing “outstanding efficacy” of 95% that may be due to patients having healthier T cells while still in early-stage treatment.

GLP-1 medications, especially for diabetes, will remain an influential cost driver in drug spending this year, supported by broader prescriber adoption and patient demand.

In this episode, ‘Psychosocial Impacts and Traditional Treatment Modalities in Vitiligo,’ the expert dermatologist explored the following questions:

Self-insured employers and other payers are the startup's customers, but Aradigm CEO and co-founder Will Shrank says the company is looking to bridge the gaps among all stakeholders in burgeoning cell and gene therapy category.

Shrank, a longtime member of the MHE editorial advisory board, discusses the mainstreaming of CAR-T therapy and still-unique aspects of gene therapy

Shrank is president and co-founder of cell and gene therapy (CGT) startup Aradigm, which is working with patients, payers, providers, and manufacturers to manage the cost and financial risk of expensive cell and gene therapy.

Bispecific antibodies could mean simpler regimens that will require fewer clinic visits, Adams said. She also mentioned the possibility of fixed-duration therapy and patients getting to the status of minimal residual disease negative faster.

After step-up dosing, treatment with bispecific antibodies does not require the use of steroids, Adams noted, so patients are spared steroid side effects. Bispecific antibody treatment advances could also mean avoiding proteasome inhibitors, which cause neuropathy, she said.

In this episode titled, ‘Understanding the Pathogenesis and Epidemiology of Vitiligo’, David Rosmarin led the conversation about the following questions:

Updated FDA labeling and NCCN recommendations are pushing more health systems and payers to adopt DPYD testing before fluoropyrimidine treatment to help reduce serious toxicities in cancer care.

New ADA 2026 guidance expands CGM beyond insulin, boosting A1C, time-in-range and cutting costs—tips for patients, providers, payers.